TABLE 6.

Lymphodepletion increased patient tolerance to high dose IL-2 administration

	Doses of IL-2 tolerated for each treatment cycle
	Treatment cycles before ablation
	1	2	3	4	5	6	7	8	9	During ablation 1	After recovery* 2
Pt#
10	8	9	6							15†	6
11	10	8	7	6						12	8
12	8	6	5							8
13	12	12	6	6	1	4	4	4	5	12	8
14	10	9	8	9	9	7	6			12	6
15	9	7	7	8	5	6	4			8	4
Average	9.5	8.5	6.5	7.3	5	5.7	4.7	4	5	11.2	6.4

Patients treated subsequently were approved to receive up to 12 doses of IL-2.

^*Three to ten weeks after administration of chemotherapy, five patients received either a second cycle of cloned T cells or other immunotherapy, including high dose IL-2 therapy.

^†Patient 10 was treated with regulatory approval to receive up to 15 doses of IL-2.